Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
Hannah L. Smith(Newcastle University), Nicola J. Curtin(Newcastle University)
Cited by 8
Related Papers
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
|Molecular Oncology|2015|24